Bayer Focuses On Pipeline To Deflect From 1Q Financial Misses

Bayer’s first quarter financial performance has been dubbed “uninspiring” by analysts; as well as sales misses, the German big pharma has ended development for certain assets.

group of businessman in black suit and holding red arrow down graph
Bayer misses in Q1; cuts clinical programs • Source: Shutterstock

Bayer AG will not pursue development of one its significant cancer therapies, Aliqopa (copanlisib), in diffuse large B-cell lymphoma (DLBCL) despite completing Phase II trials, the company noted in its first quarter financial report for 2018.

Included in Bayer’s Q1 2018 report was a list of “important” pipeline assets currently in Phase II and Phase III...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Earnings

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.